Genmab AS

Genmab AS Revenue per Share

The Revenue per Share of Genmab AS (GMAB) as of Nov 22, 2026 is 5.54 USD. In the previous year, Revenue per Share was 33.55 USD — a change of -83.50% (lower).

Revenue per Share

5.54USD

YoY

-83.50%

Last updated:

Revenue per Share of Genmab AS is 2025 5.54 USD. Revenue per Share of Genmab AS was 2024 33.55 USD. It decreases by -83.50% lower compared to the previous year.

The Genmab AS Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2023
25.04 USD
Jan 1, 2024
33.55 USD
Jan 1, 2025
5.54 USD
Jan 1, 2026 (e)
7.29 USD
Jan 1, 2027 (e)
8.82 USD
Jan 1, 2028 (e)
11.24 USD
Jan 1, 2029 (e)
12.62 USD
Jan 1, 2030 (e)
14.06 USD
The Genmab AS Revenue per Share history
YEARRevenue per ShareYoY
est14.06USD+11.42%
est12.62USD+12.26%
est11.24USD+27.45%
est8.82USD+20.99%
est7.29USD+31.68%
5.54USD-83.50%
33.55USD+33.99%
25.04USD+14.06%
21.95USD+72.52%
12.73USD-16.83%
15.30USD+87.59%
8.16USD+67.42%
4.87USD+28.18%
3.80USD+29.52%
2.93USD+53.95%
1.91USD+29.55%
1.47USD+18.07%
1.25USD+22.81%
1.01USD+29.71%
0.78USD-39.64%
1.30USD-0.64%
1.30USD-15.89%
1.55USD+28.70%
1.20USD+246.06%
0.35USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Revenue per Share of Genmab AS is 5.54 USD in 2025.

Revenue per Share of Genmab AS changed from 33.55 USD to 5.54 USD, representing a -83.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genmab AS

All Key Metrics — Genmab AS